-
Mashup Score: 1
Coronary artery disease (CAD) is a common co-morbidity in people with HIV (PWH) and impaired coronary endothelial function (CEF) plays a central role in the pathogenesis of CAD. Age-related impaired CEF among PWH, however, is not well characterized. We investigated the association between CEF and age in males and females with and without HIV using 3T magnetic resonance imaging. We measured the changes in coronary cross-sectional area (CSA) and coronary blood flow during isometric handgrip exercise, an established endothelial-dependent stressor with smaller increases in CSA and coronary blood flow indicative of impaired CEF. We included 106 PWH and 82 HIV-negative individuals. Differences in demographic and clinical characteristics between PWH and HIV-negative individuals were explored using Pearson’s chi-squared test for categorical variables and Welch’s t-test for continuous variables. Linear regression models were used to examine the association between CEF and age. CEF was significa
Source: journals.physiology.orgCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0
Division of Magnetic Resonance Research, Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD. (M.S.) Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. (T.T.B.) Department of Epidemiology and Public Health, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD (S.L.). Correspondence to: Thorsten M. Leucker, MD, PhD, 600 N. Wolfe St. Johns Hopkins Hospital-
Source: www.ahajournals.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition - 1 year(s) ago
AbstractAims. Platelet activation and endothelial dysfunction contribute to adverse outcomes in patients with acute coronary syndromes (ACS). The goals of this
Source: academic.oup.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 5LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics - PubMed - 1 year(s) ago
Lipoprotein(a) [Lp(a)] is a molecule bound to apolipoprotein(a) with some similarity to low-density lipoprotein cholesterol (LDL-C), which has been found to be a risk factor for cardiovascular disease (CVD). Lp(a) appears to induce inflammation, atherogenesis, and thrombosis. Approximately 20% of th …
Source: pubmed.ncbi.nlm.nih.govCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1Contemporary Management of Dyslipidemia - PubMed - 2 year(s) ago
The treatment of dyslipidemia continues to be a dynamic and controversial topic. Even the most appropriate therapeutic range for lipid levels-including that of triglycerides and low-density lipoprotein cholesterol-remain actively debated. Furthermore, with ever-increasing options and available treat …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0The role of proprotein convertase subtillisin/kexin type 9 in placental salvage and lipid metabolism in women with preeclampsia - 2 year(s) ago
Preeclampsia is associated with decreased maternal low-density lipoprotein cholesterol (LDL-c), which is essential for fetal growth. The underlying me…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 4Contemporary Management of Dyslipidemia - Drugs - 3 year(s) ago
The treatment of dyslipidemia continues to be a dynamic and controversial topic. Even the most appropriate therapeutic range for lipid levels—including that of triglycerides and low-density lipoprotein cholesterol—remain actively debated. Furthermore, with ever-increasing options and available treatment modalities, the management of dyslipidemia has progressed in both depth and complexity. An…
Source: SpringerLinkCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 6#CardsJC: The LODOCO2 Trial - Cardionerds Twitter Journal Club - 3 year(s) ago
LoDoCo2 Trial: Colchicine in Patients with Chronic Coronary Disease is discussed as part of the CardioNerds #CardsJC twitter journal club
Source: CardionerdsCategories: Expert Picks, Latest HeadlinesTweet-
Join us tonight for #CardsJC to discuss LoDoCo2💊 w/ FITs: @OranefoJustice & @AlizaHussainMD & Experts: @a_l_bailey @AllanLKleinMD1 @TLeucker @DrMarthaGulati @SethShayMartin @NehalMehtaMD @ErinMichos @seamuswhelton 🔗Summary & Visual Abstract: https://t.co/wOkqwOuUyr https://t.co/TC4upfKI4n https://t.co/Yz1pPqyidi
-
-
Mashup Score: 1Novel therapies to know for ASCVD prevention in 2021 and beyond - 4 year(s) ago
Cardiology Today | Significant therapeutic advancements have been achieved in the management of dyslipidemia. The ability to decrease LDL to previously unattainable levels, owing largely to the development of PCSK9 monoclonal antibodies, has illuminated two important lessons. No. 1, when it comes to LDL, data support a “lower is better” paradigm, with outcomes from FOURIER and ODYSSEY OUTCOMES…
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Novel therapies to know for ASCVD prevention in 2021 and beyond - 4 year(s) ago
Significant therapeutic advancements have been achieved in the management of dyslipidemia. The ability to decrease LDL to previously unattainable levels, owing largely to the development of PCSK9 monoclonal antibodies, has illuminated two important lessons. No. 1, when it comes to LDL, data support a “lower is better” paradigm, with outcomes from FOURIER and ODYSSEY OUTCOMES showing
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
Coronary artery endothelial function and aging in people with HIV & HIV-negative individuals | American Journal of Physiology-Heart & Circulatory Physiology @CiccaroneCenter @hopkinsheart @HopkinsMedicine @TLeucker https://t.co/oXYLwFhKBa